cemadotin and Lung-Neoplasms

A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). Previously untreated patients received this agent at a dosage of 2.5 mg/m2 as a 5-minute intravenous infusion for 5 consecutive days every 3 weeks. Between September 1997 and July 1998, 17 patients were accrued in this study. Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC.

Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Depsipeptides; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oligopeptides; Quality of Life